TWiV 1016: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Surveillance to track progress toward poliomyelitis eradication (CDC)
- Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3 (Nature)
- Evaluation of Oseltamivir to prevent hospitalization in outpatients with Influenza (JAMA)
- Viral emissions into air and environment after SARS-CoV-2 human challenge (The Lancet)
- Has COVID-19 threatened routine childhood vaccination (Health Affairs)
- Successful treatment of COVID-19 with extended duration Nirmatrelvir/Ritonavir (OFID)
- Anemia as a risk factor for disease progression in patients admitted for COVID-19 (Nature)
- Impact of fatigue as the determinant of functional limitations among patients with post-COVID-19 syndrome (BMJ)
- Post-COVID condition in patients with inflammatory rheumatic diseases (The Lancet)
- Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition (The Lancet)
- Metformin reduces SARS-CoV-2 in a Phase 3 placebo controlled clinical trial (MedRxiv)
- Persistent serum protein define an inflammatory subcategory of long COVID (Nature)
- Relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome (JTM)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1016
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Surveillance to track progress toward poliomyelitis eradication (CDC)
- Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3 (Nature)
- Evaluation of Oseltamivir to prevent hospitalization in outpatients with Influenza (JAMA)
- Viral emissions into air and environment after SARS-CoV-2 human challenge (The Lancet)
- Has COVID-19 threatened routine childhood vaccination (Health Affairs)
- Successful treatment of COVID-19 with extended duration Nirmatrelvir/Ritonavir (OFID)
- Anemia as a risk factor for disease progression in patients admitted for COVID-19 (Nature)
- Impact of fatigue as the determinant of functional limitations among patients with post-COVID-19 syndrome (BMJ)
- Post-COVID condition in patients with inflammatory rheumatic diseases (The Lancet)
- Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition (The Lancet)
- Metformin reduces SARS-CoV-2 in a Phase 3 placebo controlled clinical trial (MedRxiv)
- Persistent serum protein define an inflammatory subcategory of long COVID (Nature)
- Relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome (JTM)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1016
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.